PDCD1 and neoplasm: Our research results showed that anti-PD-1 combined with low-dose anti-VEGFR2 therapy significantly delayed tumor growth and prolonged the survival of mice in preclinical models of LUAD, revealing that anti-VEGFR2 therapy depended on different doses to affect immunotherapy.